End-of-day quote
Taipei Exchange
23:00:00 03/06/2024 BST
|
5-day change
|
1st Jan Change
|
32.5
TWD
|
+0.78%
|
|
+3.17%
|
+47.73%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
362.2
|
221.2
|
308.6
|
313.9
|
389.5
|
869
|
Enterprise Value (EV)
1 |
347.7
|
220
|
315.7
|
376.7
|
463.3
|
672.6
|
P/E ratio
|
-13.8
x
|
-18.3
x
|
-11.4
x
|
-18.2
x
|
-13.8
x
|
-11.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.86
x
|
2.12
x
|
3.31
x
|
3.53
x
|
4.38
x
|
13.4
x
|
EV / Revenue
|
5.63
x
|
2.11
x
|
3.38
x
|
4.24
x
|
5.21
x
|
10.4
x
|
EV / EBITDA
|
-15.5
x
|
-14.3
x
|
-10.7
x
|
-15.4
x
|
-12.9
x
|
-8.42
x
|
EV / FCF
|
-5.1
x
|
-38.4
x
|
-15.4
x
|
-29.3
x
|
53.2
x
|
-14.1
x
|
FCF Yield
|
-19.6%
|
-2.6%
|
-6.51%
|
-3.41%
|
1.88%
|
-7.07%
|
Price to Book
|
2.24
x
|
1.47
x
|
2.39
x
|
2.8
x
|
5.13
x
|
2.5
x
|
Nbr of stocks (in thousands)
|
19,000
|
19,000
|
19,000
|
19,000
|
19,000
|
39,500
|
Reference price
2 |
19.06
|
11.64
|
16.24
|
16.52
|
20.50
|
22.00
|
Announcement Date
|
30/03/19
|
23/03/20
|
31/03/21
|
30/03/22
|
29/03/23
|
15/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
61.79
|
104.5
|
93.34
|
88.93
|
88.97
|
64.73
|
EBITDA
1 |
-22.42
|
-15.35
|
-29.52
|
-24.47
|
-35.78
|
-79.84
|
EBIT
1 |
-26.28
|
-19.25
|
-33.43
|
-28.33
|
-40.33
|
-84.94
|
Operating Margin
|
-42.53%
|
-18.43%
|
-35.82%
|
-31.85%
|
-45.33%
|
-131.23%
|
Earnings before Tax (EBT)
1 |
-25.22
|
-11.86
|
-28.93
|
-23.78
|
-38.48
|
-82.09
|
Net income
1 |
-25.07
|
-11.86
|
-27.1
|
-17.2
|
-28.22
|
-64.64
|
Net margin
|
-40.57%
|
-11.36%
|
-29.03%
|
-19.34%
|
-31.71%
|
-99.87%
|
EPS
2 |
-1.378
|
-0.6354
|
-1.426
|
-0.9100
|
-1.490
|
-1.870
|
Free Cash Flow
1 |
-68.2
|
-5.725
|
-20.56
|
-12.85
|
8.702
|
-47.55
|
FCF margin
|
-110.37%
|
-5.48%
|
-22.03%
|
-14.45%
|
9.78%
|
-73.46%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/19
|
23/03/20
|
31/03/21
|
30/03/22
|
29/03/23
|
15/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
7.1
|
62.8
|
73.8
|
-
|
Net Cash position
1 |
14.5
|
1.23
|
-
|
-
|
-
|
196
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.2404
x
|
-2.567
x
|
-2.063
x
|
-
|
Free Cash Flow
1 |
-68.2
|
-5.72
|
-20.6
|
-12.9
|
8.7
|
-47.6
|
ROE (net income / shareholders' equity)
|
-18%
|
-7.61%
|
-19.9%
|
-18.4%
|
-38.8%
|
-38%
|
ROA (Net income/ Total Assets)
|
-8.91%
|
-4.76%
|
-7.68%
|
-6.24%
|
-9.19%
|
-13%
|
Assets
1 |
281.3
|
249.4
|
352.7
|
275.6
|
307.1
|
496.5
|
Book Value Per Share
2 |
8.520
|
7.900
|
6.800
|
5.900
|
4.000
|
8.800
|
Cash Flow per Share
2 |
2.870
|
1.580
|
1.500
|
0.5500
|
2.120
|
7.430
|
Capex
|
-
|
0.4
|
0.23
|
-
|
0.74
|
11.3
|
Capex / Sales
|
-
|
0.38%
|
0.25%
|
-
|
0.83%
|
17.38%
|
Announcement Date
|
30/03/19
|
23/03/20
|
31/03/21
|
30/03/22
|
29/03/23
|
15/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +47.73% | 39.67M | | +75.69% | 12.57B | | -24.12% | 7.4B | | +10.90% | 6.9B | | +20.88% | 5.79B | | -16.83% | 4.86B | | +19.43% | 4.27B | | -18.77% | 3.96B | | -24.00% | 2.87B | | +52.88% | 2.46B |
Medical Equipment
|